SaniMed Science Group
SaniMed Science Group is a trusted partner for early-stage MedTech startups, offering a comprehensive suite of investment, consulting, and financial support services. With deep expertise in regulatory pathways and market strategy, SaniMed provides invaluable guidance from initial concept through to FDA approval and market launch. Our consulting services include expert valuation, compliance advisory, and strategic partnerships that drive financial growth. Leveraging a strong network and industry insight, SaniMed enables MedTech innovators to secure funding, streamline regulatory approvals, and accelerate time-to-market, making it an essential resource for emerging healthcare technology ventures.
Meet Our Team
Jim Wu
Founder
Mr. Wu has been involved in the investment, healthcare, and international trade industries for over 25 years. He has extensive experience in international trade import and export, procurement and outsourcing, international business development, expanding product markets, establishing distribution networks, and international business cultural consulting. He is the founder of SaniMed Science Group, a distinguished Angel, and Early-Stage Investment Company in the USA, specializing in Health Tech industry. He is Director of Business Development of TomoWave Medical Group. He is the President of the White Mountain Medical Foundation, which promotes medical information exchange and education opportunities globally. He is Advisor of Beijing University Health Science Center Alumni Association, and the Board Member of Leadership Committee of Joint Institute between Michigan University Medicine and Peking University Health Science Center. Mr. Jim Wu, as the Founder of TomoWave Medical Group, has been accepted to the Health Tech Fall 2023 FI Core Program by The Founder Institute, which spans over 200 cities worldwide and encompasses more than 6,800 alumni companies across six continents. Mr. Wu was born and raised in China and earned a M.D. from the Medical School of Peking University, as well as an MBA from Bauer Business School at the University of Houston.
Oraevsky Alexander
Technology Advisor
Dr. Alexander, known as the "Father of International Biomedical Optoacoustic Imaging," has dedicated over 20 years to the research and industrial translation of biomedical optoacoustic imaging technology. He has received funding of nearly $20 million from institutions such as the National Institutes of Health (NIH) and has applied for 21 patents, including the world's first optoacoustic patent titled "Method and System for Optoacoustic Imaging." He has also published 11 monographs and over 200 research papers. He has been honored with the Berthold Leibinger Innovations Prize and the James Smith Award from the International Photoacoustic and Photothermal Association. Currently, Dr. Alexander serves as the CEO and CTO of TomoWave Laboratories, Inc., where he focuses on the development and commercialization of high-resolution, high-contrast, and high-sensitivity 3D optoacoustic tomography (OAT) technology for oncology and biology. He also holds the positions of CEO and General Manager at TomoWave (Suzhou) Medical Imaging Co., Ltd., an adjunct professor in the Department of Biomedical Engineering at the University of Houston and a Distinguished Professor of Medical Imaging at Guangzhou Medical University. Furthermore, Dr. Alexander has held various positions throughout his career, including being a board member and Chief Technology Officer (Vice President of Medical Technologies) at Seno Medical Instruments, Director of the Optoacoustic Imaging and Spectroscopy Laboratory at the Biomedical Engineering Center of the University of Texas Medical Branch at Galveston, adjunct assistant professor at the College of Optometry at the University of Houston, adjunct assistant professor in the Department of Electrical and Computer Engineering at Rice University, and the Santander Chair of Excellence in Electronics at Carlos III University of Madrid. Dr. Alexander graduated from the Moscow Engineering Physics Institute with a bachelor's degree in theoretical and experimental physics in 1978, from the Moscow Engineering Physics Institute with a master's degree in ultrafast laser spectroscopy of biomolecules in 1980, and from the Institute of Spectroscopy of the Soviet Academy of Sciences with a doctoral degree in spectroscopy, photochemistry, and biophysics in 1986.
Can Cui PhD, JD
Legal Advisor
Dr. Can Cui is a partner in Goodwin’s Life Sciences group and a co-leader of the firm’s Life Sciences practice in Asia. His practice focuses on technology transactions and investment in the life sciences industry, especially those transactions related to China, including cross-border technology licensing and acquisition, collaboration and strategic partnership, joint venture (JV), and other forms of investment.
Dr. Cui has extensive experience representing both licensors and licensees in US-China life sciences licensing transactions. In private equity and venture capital transactions, he regularly represents institutional and individual investors, established life sciences companies and startups in intellectual property (IP) due diligence and the negotiation and drafting of related investment documentation. He also advises clients on IP aspects of mergers and acquisitions.
Dr. Cui has deep knowledge of China’s increasingly complex regulatory landscape, including not only the IP laws, but also laws and regulations governing cross-border transactions, such as technology import and export regulations, regulations of human genetic resources, and data privacy laws and regulations. He also has rich experiences in corporate matters, patent prosecution and IP dispute resolution, which, together with his scientific background, make him a go-to person for advice in various legal matters life sciences companies may have.
In addition to his legal services to the life sciences industry, Dr. Cui is also an active participant in a wide variety of pro bono matters.
